Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

被引：0

作者：

Rackoff, Paula ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Rheumatol, New York, NY 10003 USA

来源：

CLINICAL INTERVENTIONS IN AGING | 2009年 / 4卷

关键词：

osteoporosis; fracture; SEE VOL. 176; HIP FRACTURE; VERTEBRAL FRACTURES; NONVERTEBRAL FRACTURES; ORAL BISPHOSPHONATES; RANDOMIZED-TRIAL; POOLED ANALYSIS; RISK-FACTORS; ELDERLY-MEN; PG; 1256;

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

引用

页码：207 / 214

页数：8

共 50 条

[1] Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Delmas, Pierre D.
McClung, Michael R.
Zanchetta, Jose R.
Racewicz, Artur
Roux, Christian
Benhamou, Claude-Laurent
Mang, Zulema
Eusebio, Rachelle A.
Beary, John F.
Burgio, David E.
Matzkin, Ellen
Boonen, Steven
BONE, 2008, 42 (01) : 36 - 42
[2] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
McClung, M. R.
Zanchetta, J. R.
Racewicz, A.
Roux, C.
Benhamou, C. -L.
Man, Z.
Eusebio, R. A.
Beary, J. F.
Burgio, D. E.
Matzkin, E.
Boonen, S.
Delmas, P.
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299
[3] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
M. R. McClung
J. R. Zanchetta
A. Racewicz
C. Roux
C.-L. Benhamou
Z. Man
R. A. Eusebio
J. F. Beary
D. E. Burgio
E. Matzkin
S. Boonen
P. Delmas
Osteoporosis International, 2013, 24 : 293 - 299
[4] The efficacy and tolerability of a once-a-month dosing regimen of 150 mg risedronate for the treatment of postmenopausal osteoporosis - the merit-OP study
Delmas, P. D.
McClung, M. R.
Zanchetta, J. R.
Racewicz, A.
Roux, C.
Benhamou, C. L.
Man, Z.
Eusebio, R.
Beary, J. F.
Burgio, D. E.
Boonen, S.
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S327 - S327
[5] Once-a-Month Risedronate in Postmenopausal Osteoporosis
Sunyecz, John A.
POSTGRADUATE MEDICINE, 2009, 121 (04) : 42 - 44
[6] The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
Brown, JP
Kendler, DL
McClung, MR
Emkey, RD
Adachi, JD
Bolognese, MA
Li, Z
Balske, A
Lindsay, R
CALCIFIED TISSUE INTERNATIONAL, 2002, 71 (02) : 103 - 111
[7] The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis
J.P. Brown
D.L. Kendler
M.R. McClung
R.D. Emkey
J.D. Adachi
M.A. Bolognese
Z. Li
A. Balske
R. Lindsay
Calcified Tissue International, 2002, 71 : 103 - 111
[8] Once-a-month 150 mg oral risedronate is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II study results
Ste-Marie, L. G.
Brown, J. P.
Beary, J. F.
Darbie, L.
Burgio, D. E.
Racewicz, A.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S210 - S211
[9] Efficacy and Safety of Risedronate Sodium in Treatment of Postmenopausal Osteoporosis
李裕明
张众志
邓秀玲
陈璐璐
华中科技大学学报(医学英德文版), 2005, (05) : 527 - 529
[10] Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis
Li Yuming
Zhang Zhongzhi
Deng Xiuling
Chen Lulu
Journal of Huazhong University of Science and Technology [Medical Sciences], 2005, 25 (5): : 527 - 529

← 1 2 3 4 5 →